Full Text PDF Similar Articles Mail to Author

¹Department of Oncology, Bio IRC, R&D Center for Biomedical Research, Kragujevac-Yugoslavya
²Department of Radiation Oncology, East Slovakia Institute of Oncology, Kosice-Slovakya
³Department of Radiation Oncology, Haceteppe University, School of Medicine, Ankara-Turkey DOI : 10.5505/tjo.2019.2015 Here we present a summary of existing evidence from meta-analyses and systematic reviews in the setting of locally advanced, inoperable squamous cell cancer of the head and neck, treated with radical radiotherapy and concurrent cisplatin therapy either weekly or every 3 weeks. Taken together, the data seem to indicate that there is no difference in major outcomes, including toxicity. However, caution in the interpretation of the data should be exercised due to poor quality of original studies, none of which was a prospective randomized phase III trial. Practicing clinicians should continue using their best judgment about the most appropriate treatment option in this setting, taking into account both the existing evidence and also various patient and tumor characteristics. Keywords : Cisplatin; head and neck cancer; locally advanced disease; radiotherapy